companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

AIMAX REALTY INC

NORTH YORK-Canada

Company Name:
Corporate Name:
AIMAX REALTY INC
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 1410 Victoria Park Ave,NORTH YORK,ON,Canada 
ZIP Code:
Postal Code:
M4A2L8 
Telephone Number: 4164433354 
Fax Number: 4164433354 
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
653118 
USA SIC Description:
Real Estate 
Number of Employees:
1 to 4 
Sales Amount:
Less than $500,000 
Credit History:
Credit Report:
Good 
Contact Person:
J Joshi 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
AIR CADET LEAGUE
AIR BEST LIMOUSINE & TAXI SERVICE
AINSWORTH INC
Next company profile:
AIMAX REALTY INC
AIM TRIMARK INVESTMENT INC
AIM POWER GEN CORPORATION










Company News:
  • Multi-Cancer Early Detection: cancer screening beyond todays . . .
    A promising advancement in screening is the use of multi-cancer early detection (MCED) tests, a type of liquid biopsy MCED tests are designed to identify the early presence of a wide range of cancers These blood tests aim to detect biomarkers that may suggest the presence of cancer, potentially before current, established screening methods detect it or before patients first present with
  • Testes de detecção precoce de múltiplos cânceres | Swiss Re
    Um avanço promissor na triagem é o uso de testes de detecção precoce de múltiplos cânceres (MCED), um tipo de biópsia líquida Ainda que os testes MCED estejam em desenvolvimento, eles poderão eventualmente tornar-se um rastreio de primeira linha e uma ferramenta de diagnóstico complementar
  • Multi-cancer early detection tests: a simple blood test has the . . .
    Multi-cancer early detection (MCED) blood tests have the potential to increase early detection rates of some cancers, improving survivability MCED tests may reduce the costs associated with late-stage cancer treatments; more real-world studies needed to validate their efficacy and applicability in the wider population Concerns around MCEDs include their ability to detect cancers at early
  • Exámenes de detección temprana de múltiples tipos de cáncer
    La detección temprana del cáncer mejora significativamente las tasas de supervivencia Un avance prometedor en los exámenes de detección es el uso de pruebas de detección temprana de cáncer múltiple (MCED, por sus siglas en inglés)
  • Progress with Prudence: Navigating New Multi-Cancer Tests
    As MCED tests' commercial availability expands and they are increasingly used in clinical settings, insurers must also consider their impact on disclosures and potential for anti-selection Insurers have already begun their own MCED pilot projects, exploring possible benefits for policyholders who are at a higher risk of developing cancer
  • Genetic testing in the Life Health insurance industry
    Advancements in genomic science and technology have rapidly integrated genetic testing into clinical practice, improving the diagnosis, treatment, and classification of diseases These have spurred the development of other emerging technologies, such as Multi-cancer early detection (MCED) or liquid biopsy tests, which show promise to screen for the early presence of a wide range of cancers
  • The future of excess mortality after COVID-19
    Executive summary The COVID-19 pandemic has been synonymous with excess mortality Four years on, many countries worldwide still report elevated deaths in their populations This impact appears generally independent of healthcare systems and population health It is evident even after accounting for shifting population sizes, and the range of reporting mechanisms and death classifications that
  • The potential of cancer prevention - Swiss Re
    The UK NHS-Galleri MCED trial has enrolled 140,000 individuals aged 50-77 and is awaiting results In a modelling study, this test was able to reduce late-stage cancer incidence by 78%, with a five-year cancer mortality reduction of 39% in those intercepted




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer